Inspyr Therapeutics, Inc., a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, announces it continues to strengthen its global intellectual property portfolio of adenosine receptor antagonists.
- Expansion of patent portfolio of novel adenosine immuno-modulator compounds
WESTLAKE VILLAGE, CA / ACCESSWIRE / December 10, 2020 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, announces it continues to strengthen its global intellectual property portfolio of adenosine receptor antagonists. Expansion further provides flexibility to pursue novel treatments based on the specific targets found in different types of cancer.
The company continues to execute on implementing its new corporate strategy by strengthening its portfolio and securing additional capital to pursue long-term strategic objectives and create value for stakeholders. The expansion includes 18 additional issued patents in potential future commercial markets including the United States, Europe, the United Kingdom, Asia and other geographies. This newly issued intellectual property supports the research and development of RT-AR001, a potential first-in-class adenosine receptor modulator, and further business development initiatives.
The company is now in the process of commencing corporate operations including: pre-clinical research and development, manufacturing, regulatory and business development. The company is dedicated to continuing to execute its new corporate strategy and will provide timely updates to shareholders.
About Inspyr Therapeutics, Inc.
Inspyr Therapeutics, Inc. is a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer. Our approach utilizes our proprietary delivery technology to better enhance immuno-modulation for improved therapeutic outcomes. Our potential first-in-class immune-oncology lead asset, RT-AR001, an adenosine receptor antagonist, is differentiated by its novel microparticle formulation that allows for better tumor infiltration and enhanced outcomes when administered intra-tumorally. Our patented portfolio of adenosine receptor antagonists provides flexibility to optimize treatment based on the specific targets found in each type of cancer.
Cautionary Statement Regarding Forward Looking Information:
This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Inspyr Therapeutic’s periodic reports filed with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Reports on Form 10-Q as well as and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.
SOURCE: Inspyr Therapeutics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/620315/Inspyr-Therapeutics-Strengthens-Global-Intellectual-Property
